New York, NY -- (SBWIRE) -- 01/15/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Andalay Solar Inc (OTCMKTS:WEST), XOMA Corp (NASDAQ:XOMA), Progenics Pharmaceuticals, Inc (NASDAQ:PGNX), Standard Pacific Corp (NYSE:SPF)
Andalay Solar Inc (OTCMKTS:WEST) showed a volume of 2.19million shares by the end of last trade whereas the average volume of the stock remained 1.07million shares. The stock opened the session at $0.02 but then moved to $0.0235. At that price, the stock showed a negative performance of -6.00%. Andalay Solar Inc, formerly Westinghouse Solar, Inc., is a designer and manufacturer of solar power systems and solar panels with integrated micro inverters (which the Company calls alternate current (AC) solar panels). The Company's products are designed for use in solar power systems for residential and commercial rooftop customers. The Company designs, markets and sells these solar power systems to solar installers,
Will WEST Get Buyers Even After The Recent Rally? Find Out Here
XOMA Corp (NASDAQ:XOMA) opened the session at $7.90 and closed the session at $8.32. The stock showed a positive performance of 5.45% in previous trading session. XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta).
For How Long XOMA will fight for Profitability? Read This Trend Analysis report
Progenics Pharmaceuticals, Inc (NASDAQ:PGNX) opened the session at $6.49 and closed the session at $6.77. The stock showed a positive performance of 4.64% in previous trading session. The beta of the stock remained 1.24. Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers.
Why Should Investors Buy PGNX After The Recent Gain? Just Go Here and Find Out
Standard Pacific Corp (NYSE:SPF) the stock advanced 0.69% and finished the session at $8.75. Traded with volume of 2.10 million shares in the prior session and the average volume of the stock remained 3.26 million shares. The beta of the stock remained 3.05. Standard Pacific Corp. is a geographically diversified business spans many of the housing markets, including metropolitan markets in California, Florida, the Carolinas, Texas, Arizona, and Colorado. The Company operates in two principal businesses: homebuilding and financial services (consisting of its mortgage financing and title operations).
Will SPF Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)